Stocks · News reference
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates AbCellera Biologics (NASDAQ:ABCL) with a Neutral and announces $13 price target.
AbCellera To Present Phase 2 Data On ABCL635 At IMS 20th World Congress On Menopause
AbCellera (NASDAQ:ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026
What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
Akanda Determined That It Was No Longer Going To Pursue The Cultivation Of Cannabis Or Any Future Cannabis-Related Businesses; Going To Focus Its Business Efforts On Growth, Management Of Its First Towers & Fibers Corp. Subsidiary, Potentially Other Business Targets; Declined To Pay Next Option Payment Due Under Its Amended And Restated Option To Purchase Agreement With 1107385 B.C. LTD; Company’s Right To Acquire Or Use The BC Property Under The Option Agreement Has Been Terminated
On September 24, 2026, the Board of Directors of Akanda Corp. (the "Company") determined that it was no longer going to pursue the cultivation of cannabis or any future cannabis-related businesses, including its
Why Samsara Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Samsara jumped 14.8% premarket after Q2 results beat estimates; several stocks surged, while DSS plunged 36.4% on a proposed offering.